Phillips-Medisize, in collaboration with its customer, Ascendis Pharma, was recently recognized with a third industry award for the Skytrofa Auto-Injector. The Red Dot Award recognizes the drug ...
Skytrofa is a long-acting form of somatropin. Somatropin is also called human growth hormone. Skytrofa is also considered a pegylated somatropin product. Pegylated means the medication is attached to ...
What Is Skytrofa, and Why Does It Matter? Skytrofa (lonapegsomatropin-tcgd) is a long-acting version of human growth hormone (hGH). It is already approved for children with growth hormone deficiency ...
The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. Skytrofa ® ...
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment ...
Lonapegsomatropin statistically significantly reduced trunk percent fat at week 38 compared with placebo (-1.7% vs 0.4%, respectively) in adult GHD patients. The Food and Drug Administration (FDA) has ...
(RTTNews) - Ascendis Pharma A/S (ASND) reported that its second-quarter net loss widened from last year. In addition, the company said that the U.S. Food and Drug Administration approved its Skytrofa ...
SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1] "We are delighted to have secured TGA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback